Prevalence and type distribution of human papillomavirus among women older than 18 years in Egypt: A multicenter, observational study

International Journal of Infectious Diseases

Volumn 29, Issue , 2014, Pages E226-E231

  Shaltout, Mohamed Fadel ^a   Sallam, Hassan N ^b   AbouSeeda, Maged ^c   Moiety, Fady ^b   Hemeda, Hossam ^c   Ibrahim, Ahmed ^c   Sherbini, Moutaz E L ^a   Rady, Helmy ^b   Gopala, Kusuma ^d   DeAntonio, Rodrigo ^e  

^a CAIRO UNIVERSITY   (Egypt)

^b ALEXANDRIA UNIVERSITY   (Egypt)

^c AIN SHAMS UNIVERSITY   (Egypt)

^d GlaxoSmithKline Pharmaceuticals Ltd   (India)

^e GSK   (Belgium)

Author keywords

Egypt; Epidemiology; Human papillomavirus

Indexed keywords

VIRUS DNA;

ADULT; ARTICLE; DNA DETERMINATION; EGYPT; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 62; HUMAN PAPILLOMAVIRUS TYPE 84; MAJOR CLINICAL STUDY; NONHUMAN; OBSERVATIONAL STUDY; PERSISTENT INFECTION; PRECANCER; PREVALENCE; UTERINE CERVIX CANCER; WART VIRUS; ADOLESCENT; ATTITUDE TO HEALTH; CLINICAL TRIAL; GENETICS; HEALTH BEHAVIOR; ISOLATION AND PURIFICATION; MIDDLE AGED; MULTICENTER STUDY; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PSYCHOLOGY; RISK FACTOR; YOUNG ADULT;

ADOLESCENT; ADULT; ATTITUDE TO HEALTH; EGYPT; FEMALE; GENOTYPE; HEALTH BEHAVIOR; HUMAN PAPILLOMAVIRUS 16; HUMANS; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREVALENCE; RISK FACTORS; YOUNG ADULT;

EID: 84911919382     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.07.029     Document Type: Article

References (22)

1. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol 2008, 110:S4-S7.
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
3. Arbyn M., Castellsagué X., de Sanjosé S., Bruni L., Saraiya M., Bray F., et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22:2675-2686.
4. World Health Organization Information Centre on HPV and Cancer. Human papillomavirus and related cancers in Egypt. Summary report. WHO/ICO; 2010. Available at: (accessed January 9, 2014). http://www.hpvcentre.net/statistics/reports/EGY.pdf.
5. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsague X., Shah K.V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348:518-527.
6. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
7. Descamps D., Hardt K., Spiessens B., Izurieta P., Verstraeten T., Breuer T., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009, 5:332-340.
8. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
9. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009, 5:705-719.
10. Verstraeten T., Descamps D., David M.P., Zahaf T., Hardt K., Izurieta P., et al. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Vaccine 2008, 26:6630-6638.
11. Castellsague X., Munoz N., Pitisuttithum P., Ferris D., Monsonego J., Ault K., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011, 105:28-37.
12. De Vincenzo R., Ricci C., Conte C., Scambia G. HPV vaccine cross-protection: highlights on additional clinical benefit. Gynecol Oncol 2013, 130:642-651.
13. World Health Organization. Vaccine-preventable diseases: monitoring system. 2013 global summary Egypt. WHO; 2013. Available at: (accessed January 9, 2014). http://apps.who.int/immunization_monitoring/globalsummary/countries%3Fcountrycriteria%5Bcountry%5D%5B%5D=EGY%26commit=OK.
14. el-All H.S., Refaat A., Dandash K. Prevalence of cervical neoplastic lesions and human papilloma virus infection in Egypt: National Cervical Cancer Screening Project. Infect Agents Cancer 2007, 2:12.
15. Abd El-Azim S., Lotfy M., Omr A. Detection of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cancer patients: Sharkia Governorate. Egypt. Clin Lab 2011, 57:363-371.
16. Abdel Aziz M.T., Abdel Aziz M.Z., Atta H.M., Shaker O.G., Abdel Fattah M.M., Mohsen G.A., et al. Screening for human papillomavirus (HPV) in Egyptian women by the second-generation hybrid capture (HC II) test. Med Sci Monit 2006, 12:MT43-MT49.
17. van Hamont D., van Ham M.A., Bakkers J.M., Massuger L.F., Melchers W.J. Evaluation of the SPF10-INNO LiPA human papillomavirus (HPV) genotyping test and the Roche Linear Array HPV genotyping test. J Clin Microbiol 2006, 44:3122-3129.
18. Bruni L., Diaz M., Castellsague X., Ferrer E., Bosch F.X., de Sanjose S. Cervical human papillomavirus prevalence in 5 continents: meta-analysis of 1 million women with normal cytological findings. J Infect Dis 2010, 202:1789-1799.
19. Franceschi S., Plummer M., Clifford G., de Sanjose S., Bosch X., Herrero R., et al. Differences in the risk of cervical cancer and human papillomavirus infection by education level. Br J Cancer 2009, 101:865-870.
20. Freedman L.S., Edwards B.K., Ries L.A., Young J.L. Cancer incidence in four member countries (Cyprus, Egypt, Israel, and Jordan) of the Middle East Cancer Consortium (MECC) compared with US SEER 2006, National Cancer Institute, Bethesda, MD.
21. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008 v2.0. Cancer incidence and mortality worldwide. IARC CancerBase No. 10 [Internet] 2010, International Agency for Research on Cancer, Lyon, France.
22. World Health Organization Towards a strategy for cancer control in the Eastern Mediterranean region 2009, WHO-EM/NCD/060/E/7.09/400. WHO.